This video examines the rapid growth of China’s outbound biopharma and life sciences deal activity, which reached nearly $100 billion in 2025. It highlights the increasing global recognition of Chinese biomedical innovation, the long-term development behind this momentum, and the expanding opportunities for international biopharma companies to partner with Chinese firms, access innovative assets, and strengthen development pipelines through strategic collaboration.
L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2026 L.E.K. Consulting LLC
